Pharvaris
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Grafenauweg 8, Zug, Zug, 6300, Switzerla...Phone Number
+31 712036410Website
www.pharvaris.comRevenue
$104.2 MillionStock Symbol
PHVSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Pharvaris
Pharvaris is a clinical-stage biopharmaceutical company founded in 2015 that develops oral B2-receptor antagonists as therapeutic alternatives to injected treatments. The company focuses on creating novel small molecules for hereditary angioedema (HAE) and other B2-receptor-mediated conditions. Based in the Netherlands with additional operations in Switzerland and North America, Pharvaris specializes in pharmaceutical research and development for rare disorders. The company's innovative approach aims to improve treatment options and quality of life for patients with these conditions through more convenient oral medication delivery systems.Explore more
Pharvaris Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pharvaris your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Pharvaris launches new products
Funding: Get notified immidiatlly once Pharvaris has new funding data
Earning: See what the market has to say on Pharvaris recently announced quarterly report
Check out if Pharvaris is spiking on competitors!
Click to see if Pharvaris had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Pharvaris, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Pharvaris
Check if Pharvaris has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Pharvaris as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Pharvaris is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Pharvaris is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Pharvaris.
Pharvaris financials insights
Gather financial insights about Pharvaris, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$18.3M
2019
Series B
$66M
2020
Series C
$80M
2025
Stock/Share Issuance
$201M
Pharvaris Tech Stack
A closer look at the technologies used by Pharvaris
See more technologies
Most Recent Scoops
Hiring Plans
Pharvaris has more open roles in Marketing than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Pharvaris has more open roles in Marketing than it has had at any time in the past 12 months with an increased focus that include Paper Print, and experience with Message Development, Marketing Strategies, Campaign Performance Analysis, and Market Access Strategy.
Hiring Plans
Open Position
Open Position
Project
Product Development, Research & Development, Pharmaceuticals
Pharvaris News & Media
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-releasData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, which took place from JunePharvaris Announces Annual General Meeting of Shareholders
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Acad
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pharvaris
Sign Up For FreeTo access detailed company insights
Pharvaris is a clinical-stage biopharmaceutical company founded in 2015 that develops oral B2-receptor antagonists as therapeutic alternatives to injected treatments. The company focuses on creating novel small molecules for hereditary angioedema (HAE) and other B2-receptor-mediated conditions. Based in the Netherlands with additional operations in... Read More
